Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T P Poon

Showing results (211-220 of 228) with videos related to

Pageof 23
Sort By:
Cancer Research|January 18, 2008
The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinomaZan Shen, Zhen Fan Yang, Yi Gao, et al.
Annals of Surgical Oncology|April 1, 2010
Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein markerLei Chen, David W Y Ho, Nikki P Y Lee, et al.
Molecular Systems Biology|August 27, 2010
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinomaJulja Burchard, Chunsheng Zhang, Angela M Liu, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Journal of Hepatology|September 3, 2013
Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growthChang-Chun Ling, Kevin T P Ng, Yan Shao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinomaHo Yeong Lim, Jeong Heo, Hye Jin Choi, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2016
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular CarcinomaThomas C C Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.
World Journal of Gastroenterology|May 30, 2013
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patientsTan To Cheung, Sheung Tat Fan, See Ching Chan, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinomaLing Xiao Liu, Nikki P Lee, Vivian W Chan, et al.
Pageof 23

Showing results (211-220 of 228) with videos related to

Sort By:
Pageof 23
Cancer Research|January 18, 2008
The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinomaZan Shen, Zhen Fan Yang, Yi Gao, et al.
Annals of Surgical Oncology|April 1, 2010
Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein markerLei Chen, David W Y Ho, Nikki P Y Lee, et al.
Molecular Systems Biology|August 27, 2010
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinomaJulja Burchard, Chunsheng Zhang, Angela M Liu, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Journal of Hepatology|September 3, 2013
Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growthChang-Chun Ling, Kevin T P Ng, Yan Shao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinomaHo Yeong Lim, Jeong Heo, Hye Jin Choi, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2016
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular CarcinomaThomas C C Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.
World Journal of Gastroenterology|May 30, 2013
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patientsTan To Cheung, Sheung Tat Fan, See Ching Chan, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinomaLing Xiao Liu, Nikki P Lee, Vivian W Chan, et al.
Pageof 23